<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00350181</url>
  </required_header>
  <id_info>
    <org_study_id>BMT184</org_study_id>
    <secondary_id>97168</secondary_id>
    <secondary_id>BMT184</secondary_id>
    <nct_id>NCT00350181</nct_id>
  </id_info>
  <brief_title>Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplant</brief_title>
  <official_title>Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      To evaluate the incidence of grade II-IV acute GVHD with sirolimus and mycophenolate mofetil
      GVHD prophylaxis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To explore the novel combination of sirolimus and mycophenolate mofetil (MMF) as graft versus
      host disease (GVHD) prevention in HLA matched related donor blood or marrow transplantation
      (BMT). This study will report the toxicities associated with this drug combination and also
      explore possible correlations between specific blood cell types and antibody production
      during this therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the incidence of grade II-IV acute GVHD with sirolimus and mycophenolate mofetil GVHD prophylaxis.</measure>
    <time_frame>D+100 post-transplant</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Blood and Marrow Transplant (BMT)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Diagnoses Included:

          1. Acute myelogenous leukemia (AML):

             - Age 2-60 years beyond 2nd remission or relapsed/refractory disease.

               -  Age 51-60 years of age, in first or subsequent remission or relapsed/refractory
                  disease

               -  AML with multilineage dysplasia

          2. Acute lymphoblastic leukemia (ALL):

             - Age 2-60 years beyond 2nd remission or relapsed/refractory disease

             - Age 51-60 years in first or subsequent remission or relapsed/refractory disease

          3. Chronic myelogenous leukemia (CML), beyond 2nd chronic phase or in blast crisis

          4. Myelodysplastic syndrome (MDS) including patients with World Health Organization (WHO)
             refractory anemia with excess blasts-1 (RAEB-1), RAEB-2 and therapy-related MDS

          5. Myeloproliferative disorders with poor long- term survival including myeloid
             metaplasia and myelofibrosis

          6. Non-hodgkin lymphoma (NHL) - High risk NHL in first remission - Relapsed or refractory
             NHL

          7. Hodgkin lymphoma beyond first remission

        Other Inclusion Criteria:

          1. Patients 2-60 years of age

          2. Matched related donor identified, 6/6 HLA-A, B and DRB1

          3. Karnofsky performance status &gt;= 70% or Lansky performance status &gt;= 70% or patients &lt;
             16 years old.

          4. Willingness and ability to take oral medications in pill form during the
             transplantation period.

          5. Informed consent

        Exclusion Criteria:1. Prior myeloablative, allogeneic or autologous HCT. 2. HIV infection
        3. Pregnant or lactating patients 4. Evidence of uncontrolled active infection 5. Renal
        function: serum creatinine &gt;1.5 mg/dl or 24 hour creatinine clearance &gt; 50 ml/min.

        6. Hepatic function: direct bilirubin, ALT or AST &gt; 2 x upper limit of normal 7. Pulmonary
        function: In adults, corrected diffusing capacity (DLCO) &lt; 60% predicted and in children,
        room air oxygen saturation &lt;92%.

        8. Cardiac function: In adults, left ventricular ejection fraction &lt; 45% and in children,
        shortening fraction &lt; 26%.

        9. Fasting Cholesterol &gt; 300 mg/dl or Triglycerides &gt;300 gm/dl while on lipid-lowering
        agents.

        10.Patients receiving other investigational drugs unless cleared by the Principal
        Investigator.

        11. Patients with prior malignancies except basal cell carcinoma or treated carcinoma
        in-situ. Cancer treated with curative intent &gt; 5 years will be allowed. Cancer treated with
        curative intent d 5 years will not be allowed without Protocol Chair approval.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Johnston</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2006</study_first_posted>
  <last_update_submitted>October 7, 2010</last_update_submitted>
  <last_update_submitted_qc>October 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Laura Johnston</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

